PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024
Programmed cell death-1 (PD-1) inhibitors and programmed cell death ligand 1 (PD-L1) inhibitors are considered effective alternatives for the primary treatment of recurrent metastatic cancers. However, they can induce various adverse events affecting multiple organ systems, potentially diminishing p...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2424611 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841557849349554176 |
|---|---|
| author | Qingya Song Zongliang Yu Wenping Lu Zhili Zhuo Lei Chang Heting Mei Yongjia Cui Dongni Zhang |
| author_facet | Qingya Song Zongliang Yu Wenping Lu Zhili Zhuo Lei Chang Heting Mei Yongjia Cui Dongni Zhang |
| author_sort | Qingya Song |
| collection | DOAJ |
| description | Programmed cell death-1 (PD-1) inhibitors and programmed cell death ligand 1 (PD-L1) inhibitors are considered effective alternatives for the primary treatment of recurrent metastatic cancers. However, they can induce various adverse events affecting multiple organ systems, potentially diminishing patients’ quality of life, and even leading to treatment interruptions. Adverse events related to PD-1/PD-L1 inhibitors differ from those associated with CTLA-4 inhibitors and are more commonly observed in the treatment of solid tumors. This study aimed to address the knowledge gap regarding adverse events related to PD-1/PD-L1 inhibitors. A visual bibliometric network was constructed using VOSviewer, CiteSpace, R software, and the Web of Science Core Collection (WoSCC) to quantitatively analyze this research field. Future research directions were also explored. The USA ranked first in publication count and total citations. Over time, publication types transitioned from case reports to clinical trials. Research on for nivolumab was the most prevalent. The spectrum of cancers treated by PD-1/PD-L1 inhibitors expanded beyond melanoma and lung cancer to include renal cell carcinoma, esophageal cancer, and others. Common adverse events included pneumonitis, myasthenia gravis, and vitiligo. There was a significant increase in multi-phase clinical trials and studies related to biomarkers. This study offers valuable insights for potential collaborators and institutions, highlighting trends in the study of adverse events related to PD-1/PD-L1 inhibitors. The management of these adverse events has become more refined and standardized. Biomarker research and multi-phase clinical trials are likely to be key areas of focus in future studies. |
| format | Article |
| id | doaj-art-8031809ef92b416bbcc0d815a4329002 |
| institution | Kabale University |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-8031809ef92b416bbcc0d815a43290022025-01-06T09:24:13ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2025-12-0121110.1080/21645515.2024.2424611PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024Qingya Song0Zongliang Yu1Wenping Lu2Zhili Zhuo3Lei Chang4Heting Mei5Yongjia Cui6Dongni Zhang7Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaGraduate School, Beijing University of Chinese Medicine, Beijing, ChinaDepartment of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaDepartment of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaGraduate School, Beijing University of Chinese Medicine, Beijing, ChinaGraduate School, Beijing University of Chinese Medicine, Beijing, ChinaDepartment of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaDepartment of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaProgrammed cell death-1 (PD-1) inhibitors and programmed cell death ligand 1 (PD-L1) inhibitors are considered effective alternatives for the primary treatment of recurrent metastatic cancers. However, they can induce various adverse events affecting multiple organ systems, potentially diminishing patients’ quality of life, and even leading to treatment interruptions. Adverse events related to PD-1/PD-L1 inhibitors differ from those associated with CTLA-4 inhibitors and are more commonly observed in the treatment of solid tumors. This study aimed to address the knowledge gap regarding adverse events related to PD-1/PD-L1 inhibitors. A visual bibliometric network was constructed using VOSviewer, CiteSpace, R software, and the Web of Science Core Collection (WoSCC) to quantitatively analyze this research field. Future research directions were also explored. The USA ranked first in publication count and total citations. Over time, publication types transitioned from case reports to clinical trials. Research on for nivolumab was the most prevalent. The spectrum of cancers treated by PD-1/PD-L1 inhibitors expanded beyond melanoma and lung cancer to include renal cell carcinoma, esophageal cancer, and others. Common adverse events included pneumonitis, myasthenia gravis, and vitiligo. There was a significant increase in multi-phase clinical trials and studies related to biomarkers. This study offers valuable insights for potential collaborators and institutions, highlighting trends in the study of adverse events related to PD-1/PD-L1 inhibitors. The management of these adverse events has become more refined and standardized. Biomarker research and multi-phase clinical trials are likely to be key areas of focus in future studies.https://www.tandfonline.com/doi/10.1080/21645515.2024.2424611PD-1 inhibitorsPD-L1 inhibitorsadverse eventsbibliometric analysisCiteSpace |
| spellingShingle | Qingya Song Zongliang Yu Wenping Lu Zhili Zhuo Lei Chang Heting Mei Yongjia Cui Dongni Zhang PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024 Human Vaccines & Immunotherapeutics PD-1 inhibitors PD-L1 inhibitors adverse events bibliometric analysis CiteSpace |
| title | PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024 |
| title_full | PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024 |
| title_fullStr | PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024 |
| title_full_unstemmed | PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024 |
| title_short | PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024 |
| title_sort | pd 1 pd l1 inhibitors related adverse events a bibliometric analysis from 2014 to 2024 |
| topic | PD-1 inhibitors PD-L1 inhibitors adverse events bibliometric analysis CiteSpace |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2424611 |
| work_keys_str_mv | AT qingyasong pd1pdl1inhibitorsrelatedadverseeventsabibliometricanalysisfrom2014to2024 AT zongliangyu pd1pdl1inhibitorsrelatedadverseeventsabibliometricanalysisfrom2014to2024 AT wenpinglu pd1pdl1inhibitorsrelatedadverseeventsabibliometricanalysisfrom2014to2024 AT zhilizhuo pd1pdl1inhibitorsrelatedadverseeventsabibliometricanalysisfrom2014to2024 AT leichang pd1pdl1inhibitorsrelatedadverseeventsabibliometricanalysisfrom2014to2024 AT hetingmei pd1pdl1inhibitorsrelatedadverseeventsabibliometricanalysisfrom2014to2024 AT yongjiacui pd1pdl1inhibitorsrelatedadverseeventsabibliometricanalysisfrom2014to2024 AT dongnizhang pd1pdl1inhibitorsrelatedadverseeventsabibliometricanalysisfrom2014to2024 |